ClinicalTrials.gg
CompletedNCT02718898IXORA-QUpdated Sep 16, 2019Results posted

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

A Phase 3 interventional study of Ixekizumab and Placebo in Genital Psoriasis and Psoriasis, sponsored by Eli Lilly and Company. Completed at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-16.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
12th of 22
149 · median 156
Started
2016
with 2 others
Phase 3
11 of 22
none open now
Registered
11th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 12th largest by enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.

03

Conditions studied

  • Genital Psoriasis
  • Psoriasis

Browse trials for

Keywords

  • genital
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have chronic plaque psoriasis based on a diagnosis of chronic plaque psoriasis for at least 6 months before baseline.
  • Have moderate-to-severe psoriasis in the genital area at screening and baseline.
  • Have plaque psoriasis in a nongenital area at screening and baseline.
  • Have failed to respond to, or are intolerant of, at least 1 topical therapy used for treatment of psoriasis affecting the genital area.
  • Must agree to use reliable method of , which could include abstinence, during the study and for at least 12 weeks following the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Pustular, erythrodermic, and/or guttate forms of psoriasis.
  • History of drug-induced psoriasis.
  • Have recently received certain treatments for psoriasis (in particular, within the past 4 weeks but the restriction can go up to 12 months for some treatments).
  • Have ever received treatment with ixekizumab, secukinumab, brodalumab, or another drug with a similar mode of action.
  • Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to baseline and during the study.
  • Are currently enrolled in any other clinical trial involving an product.
  • Serious disorder or illness other than plaque psoriasis.
  • Active or history of malignant disease within 5 years prior to baseline.
  • Serious infection within the last 3 months.
  • Have received a within 3 months of baseline or plan to do so during the study.
  • Have received a vaccination with Bacillus Calmette-Guérin (BCG) within the past year.
  • Pregnant or breastfeeding (lactating) women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    Ixekizumab

    Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC. Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40.

    Drug: Ixekizumab · Drug: Placebo

  • Placebo comparator
    Placebo

    Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC. Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40.

    Drug: Ixekizumab · Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)

    sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants Achieving Overall sPGA (0,1)

    The overall sPGA is the physician's global assessment of the participant's psoriasis (Ps) lesions at a given time point. Plaques were assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity was given using the anchors of 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. Overall sPGA (0,1) : An overall sPGA assessed as either 0 or 1.

    Time frame: Week 12

  2. Number of Participants With at Least a 3 Point Improvement in Genital Psoriasis Itch Numeric Rating Scale (NRS) Item Within the Genital Psoriasis Symptom Scale (GPSS)

    GPSS is a participant-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (= no severity) and 10 (worst imaginable severity).

    Time frame: Week 12

  3. Number of Participants Whose Frequency of Sexual Activity is Never or Rarely Limited by Genital Psoriasis, Utilizing the Genital Psoriasis Sexual Frequency Questionnaire (SFQ) Item 2

    The SFQ is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual frequency. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Respondents were asked to answer the questions based on their psoriasis symptoms in the genital area. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with the following response options: 0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = always. \*The SFQ is also referred to as the GenPs-SFQ (genital psoriasis sexual frequency questionnaire).

    Time frame: Week 12

  4. Number of Participants Whose Frequency of Avoiding Sexual Activity is Either Never or Rarely Limited by Genital Psoriasis in the Sexual Activity Avoidance Subscale Score of the Genital Psoriasis Sexual Impact Scale (GPSIS)

    GPSIS is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual activity. The GPSIS Sexual Activity Avoidance Subscale includes 2 items: Item 1 asks whether the participant has been sexually active in the past week. (No due to other reasons = 1, No due to genital Ps = 5) Item 2 asks how often the participant avoided sexual activity in the past week due to Genital Psoriasis. (Never = 1, rarely = 2, Sometimes = 3, Often = 4)

    Time frame: Week 12

  5. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score

    DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: 1) Symptoms and feelings 2) Daily activities 3) Leisure 4) Work and school 5) Personal relationships 6) Treatment. Response categories include: 0 = not at all; 1 = a little; 2 = a lot; 3 = very much; "not relevant" responses scored as "0" and total score range of 0 to 30; higher scores indicate poor quality of life. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, baseline body surface area (BSA) category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.

    Time frame: Baseline, Week 12

  6. Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score

    mGPASI determines participants psoriasis severity in the genital region at a given time point yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. scoring index incorporates the degree of erythema (or redness), induration (or thickness), and scaling) of the genital plaques as well as erosion, fissure, and/or ulcer as a product of the genital area involved. LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.

    Time frame: Baseline, Week 12

  7. Number of Participants With at Least a 2-Point Change in Patient's Global Assessment of Genital Psoriasis (PatGA-Genital)

    Patient's Global Assessment of Genital Psoriasis (PatGA-Genital) is a participant-administered, single-item scale on which participants are asked to rank the severity of their genital psoriasis "today" by circling a number on a 0 to 5 NRS, as follows: from 0 (clear), no genital psoriasis; to 5 (severe).

    Time frame: Week 12

  8. Change From Baseline on the Short-Form Health Survey (SF-36) Physical Component Summary (PCS)

    SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, \& baseline value and modified baseline observation carried forward (mBOCF) imputation method.

    Time frame: Baseline, Week 12

  9. Change From Baseline on the Short-Form Health Survey (SF-36) Mental Component Summary (MCS)

    SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the MCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, \& baseline value and modified baseline observation carried forward (mBOCF) imputation method.

    Time frame: Baseline, Week 12

  10. Change From Baseline in Genital Psoriasis Symptom Scale (GPSS) Total Score and Individual Items

    GPSS is a participant's-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (no severity) and 10 (worst imaginable severity). total score ranges from 0 (no severity) - 80 (worst imaginable severity) LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.

    Time frame: Baseline, Week 12

  11. Number of Participants Achieving sPGA of Genitalia (0,1) at Week 12 by Treatment-Emergent Anti-Drug Antibody (TE-ADA) Status and by Neutralizing Antibody (NAb) Status

    sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.

    Time frame: Week 12

07

Results

Posted Mar 23, 2018

Participant flow

Blinded Treatment Period
Participant flow — Blinded Treatment Period
MilestonePlacebo - Blinded TreatmentIxekizumab 80mg Q2W - Blinded TreatmentPlacebo/Ixekizumab 80mg Q4W - Open Label Treatment PeriodIxekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label TreatmentPlacebo - Post Treatment Follow-upIxeqizumab 80mg Q4W - Post Treatment Follow-up PeriodIxekizumab 80mg Q2W - Post Treatment Follow-up
Started747500000
Completed657400000
Not completed9100000
Withdrew: Adverse event5100000
Withdrew: Physician decision1000000
Withdrew: Lack of efficacy1000000
Withdrew: Lost to follow-up2000000
Open Label Treatment Period (OLTP)
Participant flow — Open Label Treatment Period (OLTP)
MilestonePlacebo - Blinded TreatmentIxekizumab 80mg Q2W - Blinded TreatmentPlacebo/Ixekizumab 80mg Q4W - Open Label Treatment PeriodIxekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label TreatmentPlacebo - Post Treatment Follow-upIxeqizumab 80mg Q4W - Post Treatment Follow-up PeriodIxekizumab 80mg Q2W - Post Treatment Follow-up
Started006574000
Completed006264000
Not completed00310000
Withdrew: Adverse event0011000
Withdrew: Lost to follow-up0002000
Withdrew: Withdrawal by subject0013000
Withdrew: Lack of efficacy0012000
Withdrew: Subject discontinued in oltp0001000
Withdrew: Ttt of undisclosed addiction-pt withdrew0001000
Post Treatment Follow-up Period
Participant flow — Post Treatment Follow-up Period
MilestonePlacebo - Blinded TreatmentIxekizumab 80mg Q2W - Blinded TreatmentPlacebo/Ixekizumab 80mg Q4W - Open Label Treatment PeriodIxekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label TreatmentPlacebo - Post Treatment Follow-upIxeqizumab 80mg Q4W - Post Treatment Follow-up PeriodIxekizumab 80mg Q2W - Post Treatment Follow-up
Started000017849
Completed000006744
Not completed00001115
Withdrew: Adverse event0000011
Withdrew: Lost to follow-up0000151
Withdrew: Withdrawal by subject0000053

Outcome measures

PrimaryNumber of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)

sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)
ParticipantsPlaceboIxekizumab 80mg Q2W
Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)655
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 33.80 · 95% CI 12.39 to 92.23
SecondaryNumber of Participants Achieving Overall sPGA (0,1)

The overall sPGA is the physician's global assessment of the participant's psoriasis (Ps) lesions at a given time point. Plaques were assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity was given using the anchors of 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. Overall sPGA (0,1) : An overall sPGA assessed as either 0 or 1.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving Overall sPGA (0,1)
ParticipantsPlaceboIxekizumab 80mg Q2W
Number of Participants Achieving Overall sPGA (0,1)255
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 102.55 · 95% CI 22.79 to 461.43
SecondaryNumber of Participants With at Least a 3 Point Improvement in Genital Psoriasis Itch Numeric Rating Scale (NRS) Item Within the Genital Psoriasis Symptom Scale (GPSS)

GPSS is a participant-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (= no severity) and 10 (worst imaginable severity).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With at Least a 3 Point Improvement in Genital Psoriasis Itch Numeric Rating Scale (NRS) Item Within the Genital Psoriasis Symptom Scale (GPSS)
ParticipantsPlaceboIxekizumab 80mg Q2W
Number of Participants With at Least a 3 Point Improvement in Genital Psoriasis Itch Numeric Rating Scale (NRS) Item Within the Genital Psoriasis Symptom Scale (GPSS)537
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 16.27 · 95% CI 5.71 to 46.40
SecondaryNumber of Participants Whose Frequency of Sexual Activity is Never or Rarely Limited by Genital Psoriasis, Utilizing the Genital Psoriasis Sexual Frequency Questionnaire (SFQ) Item 2

The SFQ is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual frequency. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Respondents were asked to answer the questions based on their psoriasis symptoms in the genital area. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with the following response options: 0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = always. \*The SFQ is also referred to as the GenPs-SFQ (genital psoriasis sexual frequency questionnaire).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Whose Frequency of Sexual Activity is Never or Rarely Limited by Genital Psoriasis, Utilizing the Genital Psoriasis Sexual Frequency Questionnaire (SFQ) Item 2
ParticipantsPlaceboIxekizumab 80mg Q2W
Number of Participants Whose Frequency of Sexual Activity is Never or Rarely Limited by Genital Psoriasis, Utilizing the Genital Psoriasis Sexual Frequency Questionnaire (SFQ) Item 2929
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 13.57 · 95% CI 4.57 to 40.29
SecondaryNumber of Participants Whose Frequency of Avoiding Sexual Activity is Either Never or Rarely Limited by Genital Psoriasis in the Sexual Activity Avoidance Subscale Score of the Genital Psoriasis Sexual Impact Scale (GPSIS)

GPSIS is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual activity. The GPSIS Sexual Activity Avoidance Subscale includes 2 items: Item 1 asks whether the participant has been sexually active in the past week. (No due to other reasons = 1, No due to genital Ps = 5) Item 2 asks how often the participant avoided sexual activity in the past week due to Genital Psoriasis. (Never = 1, rarely = 2, Sometimes = 3, Often = 4)

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Whose Frequency of Avoiding Sexual Activity is Either Never or Rarely Limited by Genital Psoriasis in the Sexual Activity Avoidance Subscale Score of the Genital Psoriasis Sexual Impact Scale (GPSIS)
ParticipantsPlaceboIxekizumab 80mg Q2W
Number of Participants Whose Frequency of Avoiding Sexual Activity is Either Never or Rarely Limited by Genital Psoriasis in the Sexual Activity Avoidance Subscale Score of the Genital Psoriasis Sexual Impact Scale (GPSIS)923
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 9.84 · 95% CI 3.08 to 31.40
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score

DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: 1) Symptoms and feelings 2) Daily activities 3) Leisure 4) Work and school 5) Personal relationships 6) Treatment. Response categories include: 0 = not at all; 1 = a little; 2 = a lot; 3 = very much; "not relevant" responses scored as "0" and total score range of 0 to 30; higher scores indicate poor quality of life. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, baseline body surface area (BSA) category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
units on a scalePlaceboIxekizumab Q2W
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score-1.4 ± 0.62-9.7 ± 0.59
Statistical analysis
  • Placebo vs Ixekizumab Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -8.4 · 95% CI -10.1 to -6.7
SecondaryChange From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score

mGPASI determines participants psoriasis severity in the genital region at a given time point yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. scoring index incorporates the degree of erythema (or redness), induration (or thickness), and scaling) of the genital plaques as well as erosion, fissure, and/or ulcer as a product of the genital area involved. LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score
units on a scalePlaceboIxekizumab 80mg Q2W
Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score-3.9 ± 1.56-23.9 ± 1.48
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -20.0 · 95% CI -24.3 to -15.8
SecondaryNumber of Participants With at Least a 2-Point Change in Patient's Global Assessment of Genital Psoriasis (PatGA-Genital)

Patient's Global Assessment of Genital Psoriasis (PatGA-Genital) is a participant-administered, single-item scale on which participants are asked to rank the severity of their genital psoriasis "today" by circling a number on a 0 to 5 NRS, as follows: from 0 (clear), no genital psoriasis; to 5 (severe).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With at Least a 2-Point Change in Patient's Global Assessment of Genital Psoriasis (PatGA-Genital)
ParticipantsPlaceboIxekizumab 80mg Q2W
Number of Participants With at Least a 2-Point Change in Patient's Global Assessment of Genital Psoriasis (PatGA-Genital)1151
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 13.95 · 95% CI 6.12 to 31.80
SecondaryChange From Baseline on the Short-Form Health Survey (SF-36) Physical Component Summary (PCS)

SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, \& baseline value and modified baseline observation carried forward (mBOCF) imputation method.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Short-Form Health Survey (SF-36) Physical Component Summary (PCS)
units on a scalePlaceboIxekizumab 80mg Q2W
Change From Baseline on the Short-Form Health Survey (SF-36) Physical Component Summary (PCS)0.687 ± 0.79985.193 ± 0.7942
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · ANCOVA · p = <0.001 · Mean difference (final values): 4.506 · 95% CI 2.264 to 6.748
SecondaryChange From Baseline on the Short-Form Health Survey (SF-36) Mental Component Summary (MCS)

SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the MCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, \& baseline value and modified baseline observation carried forward (mBOCF) imputation method.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline on the Short-Form Health Survey (SF-36) Mental Component Summary (MCS)
units on a scalePlaceboIxekizumab 80mg Q2W
Change From Baseline on the Short-Form Health Survey (SF-36) Mental Component Summary (MCS)2.186 ± 0.73333.982 ± 0.7281
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · ANCOVA · p = 0.085 · Mean difference (final values): 1.797 · 95% CI -0.253 to 3.847
SecondaryChange From Baseline in Genital Psoriasis Symptom Scale (GPSS) Total Score and Individual Items

GPSS is a participant's-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (no severity) and 10 (worst imaginable severity). total score ranges from 0 (no severity) - 80 (worst imaginable severity) LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Genital Psoriasis Symptom Scale (GPSS) Total Score and Individual Items
units on a scalePlaceboIxekizumab 80mg Q2W
Total Score-2.82 ± 2.190-31.57 ± 2.070
Itch-0.21 ± 0.290-4.02 ± 0.274
Pain-0.34 ± 0.294-3.84 ± 0.278
Discomfort-0.42 ± 0.298-4.27 ± 0.282
Stinging-0.51 ± 0.298-3.74 ± 0.281
Burning-0.53 ± 0.289-3.73 ± 0.273
Redness-0.63 ± 0.287-4.45 ± 0.272
Scaling-0.02 ± 0.273-3.80 ± 0.259
Cracking-0.19 ± 0.280-3.74 ± 0.264
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -28.75 · 95% CI -34.72 to -22.78
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.81 · 95% CI -4.60 to -3.02
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.50 · 95% CI -4.30 to -2.70
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.85 · 95% CI -4.66 to -3.04
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.23 · 95% CI -4.04 to -2.42
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.20 · 95% CI -3.99 to -2.41
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.81 · 95% CI -4.59 to -3.03
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.78 · 95% CI -4.53 to -3.03
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -3.55 · 95% CI -4.31 to -2.79
SecondaryNumber of Participants Achieving sPGA of Genitalia (0,1) at Week 12 by Treatment-Emergent Anti-Drug Antibody (TE-ADA) Status and by Neutralizing Antibody (NAb) Status

sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants Achieving sPGA of Genitalia (0,1) at Week 12 by Treatment-Emergent Anti-Drug Antibody (TE-ADA) Status and by Neutralizing Antibody (NAb) Status
ParticipantsPlaceboIxekizumab 80mg Q2W
TE-ADA positive—5
TE-ADA negative650
NAb inconclusive—5

Adverse events

Collected over Up to 667 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo - Blinded Treatment Period0/74 (0%)1/74 (1.4%)19/74 (25.7%)
Ixekizumab 80 mg Q2W - Blinded Treatment Period0/75 (0%)0/75 (0%)21/75 (28%)
Placebo/Ixekizumab 80mg Q4W - Open Label Treatment Period0/65 (0%)2/65 (3.1%)28/65 (43.1%)
Ixekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label Treatment0/74 (0%)5/74 (6.8%)27/74 (36.5%)
Placebo - Post Treatment Follow-up0/1 (0%)0/1 (0%)0/1 (0%)
Ixeqizumab 80mg Q2W - Post Treatment Follow-up Period0/49 (0%)2/49 (4.1%)1/49 (2%)
Ixekizumab 80mg Q4W - Post Treatment Follow-up0/78 (0%)1/78 (1.3%)0/78 (0%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlacebo - Blinded Treatment PeriodIxekizumab 80 mg Q2W - Blinded Treatment PeriodPlacebo/Ixekizumab 80mg Q4W - Open Label Treatment PeriodIxekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label TreatmentPlacebo - Post Treatment Follow-upIxeqizumab 80mg Q2W - Post Treatment Follow-up PeriodIxekizumab 80mg Q4W - Post Treatment Follow-up
AppendicitisInfections and infestations0/740/750/650/740/11/490/78
CellulitisInfections and infestations0/740/751/650/740/11/490/78
Benign prostatic hyperplasiaReproductive system and breast disorders0/740/750/491/560/10/490/78
Extradural haematomaInjury, poisoning and procedural complications0/740/751/650/740/10/490/78
ColitisGastrointestinal disorders0/740/750/651/740/10/490/78
Pancreatitis acuteGastrointestinal disorders1/740/750/650/740/10/490/78
CholelithiasisHepatobiliary disorders0/740/750/651/740/10/490/78
Escherichia bacteraemiaInfections and infestations0/740/750/651/740/10/490/78
SepsisInfections and infestations0/740/750/651/740/10/490/78
Suicide attemptPsychiatric disorders0/740/750/651/740/10/490/78
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlacebo - Blinded Treatment PeriodIxekizumab 80 mg Q2W - Blinded Treatment PeriodPlacebo/Ixekizumab 80mg Q4W - Open Label Treatment PeriodIxekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label TreatmentPlacebo - Post Treatment Follow-upIxeqizumab 80mg Q2W - Post Treatment Follow-up PeriodIxekizumab 80mg Q4W - Post Treatment Follow-up
Upper respiratory tract infectionInfections and infestations5/7412/7510/656/740/10/490/78
Injection site reactionGeneral disorders0/745/7510/653/740/10/490/78
NasopharyngitisInfections and infestations4/742/759/657/740/10/490/78
Vulvovaginal discomfortReproductive system and breast disorders0/740/750/650/74—1/110/21
HeadacheNervous system disorders4/743/752/656/740/10/490/78
ArthralgiaMusculoskeletal and connective tissue disorders0/740/750/655/740/10/490/78
Vulvovaginal candidiasisInfections and infestations0/740/751/160/180/10/490/78
Bacterial vaginosisInfections and infestations0/740/750/161/180/10/490/78
Vulvovaginal mycotic infectionInfections and infestations0/740/750/161/180/10/490/78
DysmenorrhoeaReproductive system and breast disorders0/740/750/161/180/10/490/78

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboIxekizumab 80mg Q2WTotal
Mean44.4 ± 12.5543.1 ± 12.9543.7 ± 12.72
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIxekizumab 80mg Q2WTotal
Female171936
Male5756113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboIxekizumab 80mg Q2WTotal
Hispanic or Latino141327
Not Hispanic or Latino5760117
Unknown or Not Reported325
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIxekizumab 80mg Q2WTotal
American Indian or Alaska Native011
Asian7310
Native Hawaiian or Other Pacific Islander000
Black or African American202
White6467131
More than one race145
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)PlaceboIxekizumab 80mg Q2WTotal
Canada161329
Puerto Rico4711
Austria448
Netherlands235
Turkey347
Belgium347
United States313162
Australia11920
sPGA of Genitalia
sPGA of Genitalia(units on a scale)PlaceboIxekizumab 80mg Q2WTotal
Mean3.5 ± 0.533.4 ± 0.613.4 ± 0.57
08

Study locations

34 sites
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Olympian Clinical Research
    Tampa, Florida 33609, United States
  • Advanced Medical Research
    Sandy Springs, Georgia 30328, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46256, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Clinical Partners LLC
    Johnston, Rhode Island 02919, United States
  • Modern Research Associates PLLC
    Dallas, Texas 75231, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Pflugerville Dermatology Clinical Research Center
    Pflugerville, Texas 78660, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adelaide, 5073, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carlton, 3053, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Darlinghurst, 2010, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Woolloongabba, 4102, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Graz, 8036, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wien, 1090, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wien, 1130, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1090, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1200, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gent, 9000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    London, N6A 3H7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Markham, L3P1X2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Montreal, H2K4L5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Quebec, G1V 4X7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Surrey, V3V 0C6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergen op Zoom, 4624 VT, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Breda, 4818 CK, Netherlands
  • GCM Medical Group PSC
    San Juan, 00909, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bursa, 16059, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gaziantep, 27310, Turkey
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Istanbul, 34093, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Feb 2017 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2016
First posted
Mar 24, 2016
Start
Apr 2016
Primary completionActual
Feb 22, 2017
CompletionActual
Feb 21, 2018
Results first posted
Mar 23, 2018
Last update
Sep 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02718898
Responsible party
Sponsor
First posted
Mar 24, 2016
Start date
Apr 2016
Primary completion
Feb 22, 2017
Completion
Feb 21, 2018
Results posted
Mar 23, 2018
Last update
Sep 16, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion